METHODS: We utilised a multicentre European retrospective patient cohort of patients treated with the Combat BRS system. Each treatment instillation comprised of MMC with hyperthermia delivered at 43 C over 60 minutes. BCG-unresponsive NMIBC (urothelial carcinoma) was defined as papillary disease AE carcinoma in situ (CIS) within 12 months of last instillation of adequate BCG, or recurrent high grade papillary disease within 6 months of last instillation of adequate BCG therapy, or stage T1 disease at first 3 month cystoscopy following induction BCG. Primary endpoint was the 12-month recurrence-free survival (RFS) and the progression-free survival (PFS).
INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
has been showed to be feasible and effective in a sub-set of patients with recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-NMIBC). The aim of this study is to up-date the clinical outcome and investigate the pathological results of patients who failed to remain under AS and required an endoscopic resection.
METHODS: This is a prospective observational cohort study of patients with a previous pathologically confirmed LG NMIBC, who experienced recurrence during follow-up and accepted to undergo AS (protocol ICH/1390: Active surveillance for non-muscle invasive bladder cancer -Bladder Cancer Italian Active Surveillance -BIAS project). AS monitoring consisted of cytology and in-office flexible cystoscopy every 3 months for the first year, and then every six months annually. The primary end-point was to investigate the pathological results of patients who failed to remain in AS according to previous published criteria. The secondary outcome was to up-date the clinical results of our previous series. Data were complemented by descriptive statistical analysis and univariable and multivariable proportional hazard Cox regression.
RESULTS: Overall 167 patients, for 181 AS events, were included. Sixty-one (33.7%) events over 181 were deemed to require treatment (TURBT) because positive cytology (#10), gross-haematuria (#11), increases of number (#15), of size (#17) or both (#8). The median time on AS was 14 months 
INTRODUCTION AND OBJECTIVES:
The gold standard method used to detect and monitor bladder cancer is cystoscopy, which leads to high diagnostic costs and a high patient burden. The currently available non-invasive approaches either show unsatisfying sensitivity in low-grade tumors or possess limited specificity. This study aimed to develop a new non-invasive strategy based on urine methylation biomarker to diagnose bladder cancer effectively.
METHODS: To identify the bladder cancer specific markers, genome-wide methylation analysis was performed on 21 paired bladder tumors and normal tissues from The Cancer Genome Atlas (TCGA) cohort, and 20 paired bladder tumors and normal tissues from Sun Yat-sen Memorial Hospital (SYMH) cohort. Next, Time of Flight Mass Spectrometer (TOF-MS) analysis was performed to access markers efficiency in large cohort. We enrolled 423 patients diagnosed with bladder cancer, 82 healthy participants and 276 controls with benign diseases from SYMH cohort. DNA of 781 urine samples extracted from the urinary cells and bisulfite modificated, and methylation status was analyzed using TOF-MS. In training set, 314 urine samples were used to develop a gene classifier by LASSO regression. An additional 467 urine samples were analyzed using the 5-gene classifier for independent validation. RESULTS: We firstly identified 40 significant methylation markers in a combined analysis of TCGA cohort and SYMH cohort. 28 of 40 markers showed good concordance (87.0%) in the assessments of patient tumor tissues and urine. The TOF-MS based methylation classifier yield a good AUC of 0.915 (with a sensitivity of 89.3% and a specificity of 83.6%) in the training group. The validation group also showed an AUC of 0.903, with a sensitivity of 88.1% and a specificity of 82.4%. The methylation classifier also exhibited a significantly improved sensitivity compared to voided urine cytology and FISH. In addition, this approach could analyze 128 samples in max one time and provide clinical report less than 2 days, which facilitated doctor make decision on time.
CONCLUSIONS: TOF-MS based urine DNA methylation classifier showed high accuracy and strong diagnostic power, even in earlystage/low-grade tumor patients. Therefore, it may be used as a noninvasive fast and high-through approach for diagnosis and recurrence surveillance in bladder cancer prior to the use of cystoscopy, which would greatly reduce the burden on patients.
